Is Facebook the Place for FDA? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Is Facebook the Place for FDA?
Social media tools have taken over many aspects of our lives, now including regulatory info.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 14

If you haven't seen it yet, FDA has a Facebook page. In fact, as of this writing, the agency had nearly 4000 "friends" and more than 150 related links on its page ( http://www.facebook.com/fda/). Among the agency's "favorite pages" are the CDC, the White House, Aids.gov, and Healthcare.gov. FDA and the US government as a whole are trying to be more transparent and open about the way they do things, but it's unclear whether a Facebook page is the right approach, or garnering the right audience.

For example, one friend of the FDA page located outside the US asks on the agency's Facebook wall, why he can't send a carton of cigarettes to his friend in New Jersey for his birthday. Others have used the site to post negative comments about regulatory policies and initiatives.

The agency has online supporters, too. One friend comments that people would not be able to trust drugs, food, cosmetics, medical devices, and more if it weren't for FDA's activities. He writes, "I would love to see how this country would operate with no FDA and no regulations." Others use the page to ask questions about drug approvals or to lobby for their own pharma or healthcare causes.

To date, FDA does not seem to be responding to these comments or questions. Instead, the agency uses the page to make announcements about new initiatives, to post press releases, and so forth. FDA also has a more serious LinkedIn page and a Twitter account, the latter of which it has used to release recall alerts to the public rather quickly. Pharmaceutical Technology would like to hear your thoughts on FDA's use of social media tools and how you use them in your day-to-day work.

Angie Drakulich is the managing editor of Pharmaceutical Technology.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here